Ïû»¯ÏµÍ³Ö×Áö/²¡Àíѧ,digestive system neoplasms/pathologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ä¶¾ËØ»ùÒò,Melittin geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Îøµ°°×P,selenoprotein PÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
MC,Mass customizationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÃâÒßÕ³¸½,immune adherenceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÁÙ´²ÉúÎïѧÐÐΪ,Clinical biological behaviorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
EGFRÒÖÖÆ¼Á,EGFR inhibitorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Éñ¾ÄÚ·ÖÃÚÁö,Neuroendocrine TumorsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¾À¨Ô¼¼¡Í¾¾¶,Transsphincteric ApproachÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÇòÐÎÌå,coccoid formÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Á×µ°°×Á×Ëáø,phosphoprotein phosphataseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ºÚ¼¬Æ¤²¡,acanthosis nigricansÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
½á³¦Ö×Áö/²¡Àíѧ,colonic neoplasms/pathologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
DAPK»ùÒò,DAPK geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÁªºÏÔàÆ÷Çгý,multivisceral resectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÒÈÏÙÖ×Áö/ÖÎÁÆ,Pancreatic Neoplasms/therÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÎǺϿڳöѪ,anastomotic bleedingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ȫϵĤÇгý,Total mesorectal excisionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
VEGFmRNA,VEGF mRNAÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸Î×ªÒÆÁö,Hepatic metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
DixonÊÖÊõ,dixon operationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·úÄòà×à¤/ͶҩºÍ¼ÁÁ¿,fluorouracil/administration & dosageÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
NK4»ùÒò,NK4 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Æô¶¯Çø,promoterÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÁÙ´²²¡Àí·ÖÎö,Clinicopathologic analysisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µç×Ó¼ÆËã»úÌå²ãÉãÓ°,Computed tomographyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
É¢·¢ÐԴ󳦰©,Sporadic colorectal cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸¹Ä¤Ö×Áö,Peritoneal neoplasmsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ϸ°û¶¾ËØÏà¹Ø»ùÒòA,Cytotoxin associated gene AÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
³É±¾-ЧÓ÷ÖÎö,Cost-Utility analysisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
½éÈëÐÔÈÈ»¯ÁÆ,Interventional heated chemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¾Æ¤¾¸Îµ¨¹ÜÒýÁ÷Êõ,Percutaneous transhepatic cholangial drainageÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
BxPC-3ϸ°û,BxPC-3 cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÖÖϵͻ±ä,germline mutationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ƽ°å¿Ë¡Ðγɷ¨,Colony-forming assayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
MAD2»ùÒò,MAD2 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×éÖ¯¶àëÄ¿¹Ô,Tissue polypeptide antigenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼¡´¼ÁùÁ×Ëá,inositol hexaphosphateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ѫ¹ÜÇгý,Vascular resectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Caveolin-1»ùÒò,Caveolin-1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö°©ÐÔÊÔÑé,carcinogenicity testsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼×Ì¥µ°°×ÒìÖÊÌå,alpha-fetoprotein variantÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÄÚ¾µÉ¸²é,Endoscopic screeningÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸ÎÖ×Áö/Á÷Ðв¡Ñ§,liver neoplasms/epidemiologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Êõǰ·Å»¯ÁÆ,preoperative radiochemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸´·¢°©,Recurrent cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
±£ÁôÅèÇ»×ÔÖ÷Éñ¾,Pelvic autonomic nerve preservationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
E-cadherin»ùÒò,E-cadherin geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
´Èµ¤½ºÄÒ,Cidan capsuleÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÁܰÍÉÏÆ¤ÁöÑù°©,lymphoepithelioma-like carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
DNAËðÉË¼ì¿Øµã,DNA damage checkpointÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
EGFRµ°°×,EGFR proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÁܰͽáÇå³ýÊõ,Lymph node dissectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÔʼÉñ¾ÍâÅß²ãÁö,primitive neuroectodermal tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
TGF¦Â1»ùÒò,TGF¦Â1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÐòÁÐȱʧ,sequence deletionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
È©ÍÑÇâø,Aldehyde dehydrogenaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹ý¼ÌÃâÒßÁÆ·¨,adoptive immunotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹Ü״θ,gastric tubeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
³ÖÐøµÎ×¢,continuous infusionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
½ª»ÆËØ¢ó,curcumin ¢óÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö±³¦Àà°©,Rectal carcinoidÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
´ÅÁ÷ÌåÈÈÁÆ,magnetic fluid hyperthermiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
DNA¸Éϵ±¶Ìå,DNA stemline ploidyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ïû»¯ÏµÍ³Ö×Áö/Ò©ÎïÁÆ·¨,digestive system neoplasms/drug therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ô·¢ÐÔθÁܰÍÁö,Primary gastric lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
½»½çÐÔÖ×Áö,borderline tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
GTP½áºÏµ°°×,GTP-binding proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·°»¯ÄÆ,sodium vanadateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸¹Ç»¾µ¸ÎÇгýÊõ,laparoscopic hepatectomyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¾µ¼¹Ü¶¯Âö»¯ÁÆË¨Èû,Transcatheter arterial chemoembolizationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Éñ¾ÍøÂç(¼ÆËã»ú),neural networks(computer)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÄÉÃ×·Ðʯ,nanosized zeoliteÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ÅÉäÕï¶Ï,Diagnostic RadiologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼Ò×åÐÔθ°©,familial gastric cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Lewis¿¹Ô,Lewis antigenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
PANC-1ϸ°û,PANC-1 cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Á¢ÌåÊÊÐηÅÉäÖÎÁÆ,Three-dimensional conformal radiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÄñÜÕËá»·»¯Ã¸,guanylate cyclaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÔçÆÚ´ó³¦°©,early colorectal carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Âѳ²½»½çÐÔÖ×Áö,Borderline ovarian tumorsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
MLH1»ùÒò,MLH1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ʵÐÔ¼ÙÈéÍ·×´Áö,Solid pseudopapillary tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÈËθ°©Ï¸°û,Human gastric carcinoma cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÌÇÁ´¿¹Ô19-9,carbohydrate antigen 19-9Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
²ãð¤Á¬µ°°×ÊÜÌå,laminin receptorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ʳ¹ÜÖ×Áö/Íâ¿ÆÊÖÊõ,Esophageal neoplasms/surgeryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶ËÁ£Ã¸´ß»¯Ñǵ¥Î»,hTERTÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
HBV X»ùÒò,HBV X geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÄÚ¾µÕï¶Ï,Endoscopic diagnosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶àϸ°ûÄÍÒ©,multicellular resistanceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼äÒ¶ÐÔÖ×Áö,Mesenchymal tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Notch1»ùÒò,Notch1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÖÜÆÚËØÒÀÀµ¼¤Ã¸ÒÖÖÆ¼Áp27,Cyclin-Dependent Kinase Inhibitor p27Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»ºÊÍ»¯ÁÆ,Sustained-release chemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ð¤ÒºÏÙ°©,mucinous carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
H22ϸ°ûÖê,H22 cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Äý¹ÌÐÔ»µËÀ,Coagulative necrosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ô·¢ÐÔ¸Îϸ°û¸Î°©,primary hepatocellular carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸Î¶¯¾²Âöðü,Hepatic arteriovenous fistulaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«

|